Stock Events

Stock Events

Genprex 

€0.18
100
+€0+0% Tuesday 06:59

Statistics

Day High
0.18
Day Low
0.18
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
408,600
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

3JunExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Next
Next
-21
-14.14
-7.27
-0.41
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-40.58MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2DE.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. has a broad portfolio of cancer therapies, including gene therapies, making it a major competitor in the oncology market.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics, Inc. focuses on genomic medicine, including gene therapy, gene editing, and gene regulation, competing in the same innovative treatment space as Genprex.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics AG is a leader in gene editing technology, which can be applied to cancer treatment, making it a competitor in the gene therapy market.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics, Inc. is involved in CRISPR/Cas9 gene editing, a cutting-edge technology for treating genetic diseases and cancer, competing with Genprex's gene therapy approach.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine, Inc. works on gene editing technologies, including CRISPR, for the treatment of serious diseases, offering an alternative to Genprex's therapies.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals, Inc. focuses on RNAi (RNA interference) therapeutics for the treatment of genetic diseases, indirectly competing with Genprex's gene therapy approach by offering a different method of genetic intervention.

About

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Show more...
CEO
Mr. John Rodney Varner
Employees
31
Country
DE
ISIN
US3724463027
WKN
000A41L3N

Listings

LSE
GB
0A8I.LSE
F
DE
2DE.F
XNAS
US
GNPX
BOATS
BOATS
GNPX.BOATS

0 Comments

Share your thoughts

FAQ

What is Genprex stock price today?▼
The current price of 2DE.F is €0.18 EUR — it has increased by +0% in the past 24 hours. Watch Genprex stock price performance more closely on the chart.
What is Genprex stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Genprex stocks are traded under the ticker 2DE.F.
What is Genprex market cap?▼
Today Genprex has the market capitalization of 408,600
When is the next Genprex earnings date?▼
Genprex is going to release the next earnings report on June 03, 2026.
What is Genprex revenue for the last year?▼
Genprex revenue for the last year amounts to 0 EUR.
What is Genprex net income for the last year?▼
2DE.F net income for the last year is -40.58M EUR.
How many employees does Genprex have?▼
As of April 04, 2026, the company has 31 employees.
In which sector is Genprex located?▼
Genprex operates in the Health Care sector.
When did Genprex complete a stock split?▼
The last stock split for Genprex was on October 21, 2025 with a ratio of 1:50.
Where is Genprex headquartered?▼
Genprex is headquartered in Austin, DE.